Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.58
+0.18 (2.43%)
At close: Apr 15, 2025, 4:00 PM
7.57
-0.01 (-0.13%)
After-hours: Apr 15, 2025, 7:43 PM EDT
Arvinas Revenue
In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth. Arvinas had revenue of $59.20M in the quarter ending December 31, 2024, a decrease of -237.35%.
Revenue (ttm)
$263.40M
Revenue Growth
+235.54%
P/S Ratio
2.07
Revenue / Employee
$612,558
Employees
430
Market Cap
521.29M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ARVN News
- 11 days ago - Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study - Benzinga
- 11 days ago - Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation - GlobeNewsWire
- 19 days ago - Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases - GlobeNewsWire
- 20 days ago - Top 3 Health Care Stocks That Are Set To Fly This Month - Benzinga
- 5 weeks ago - Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial - Benzinga
- 5 weeks ago - Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study - Reuters
- 5 weeks ago - Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial - GlobeNewsWire
- 6 weeks ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire